Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
FiercePharma2d
Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...
Novo Nordisk Shares Seen Outpacing Lilly’s After Summer Stumble
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...
STAT4d
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Charting, Price Performance, News & Related Contracts.
Novo Nordisk posts Phase 3 win for obesity drug in MASH
Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
Novo Nordisk Reports Positive ESSENCE Trial Results
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that ...
Novo Nordisk: Be Cautious About Buying The Dip
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
FiercePharma3d
Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant
Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...
Novo Nordisk Reports Headline Results From Part 1 Of ESSENCE Trial With Semaglutide
Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a phase 3, 240-week, double-blinded trial ...